Legal & General Group
GENB

Legal & General Group’s Generate Biomedicines GENB Stock Holding History

Legal & General Group’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40K Buy
+2,374
New +$32.3K ﹤0.01% 2849

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Legal & General Group's GENB Position: Q2 2026 in Review

Legal & General Group opened a new position in Generate Biomedicines (GENB) in Q2 2026: 2,374 shares worth $40K. The stake represents ﹤0.01% of the portfolio and ranks #2849 among its holdings.

86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Legal & General Group held 2,374 shares of Generate Biomedicines worth $40K as of Q2 2026.
  • Generate Biomedicines was a new Legal & General Group position in Q2 2026.
  • Generate Biomedicines made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2849 holding.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.